Dalfampridine may improve walking ability: phase III results


A phase III trial of dalfampridine, or  4-aminopyridine in an oral extended-release formulation, has found that the agent appears to improve walking ability in MS patients (Goodman et al. Ann Neurol 2010; 68: 494-502).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page